Brief: Theravet Extends Exclusive Worldwide Licence With Graftys

Theravet SA

03/11/2021 06:33

Nov 3 (Reuters) - THERAVET SA  ALVET.PA :
    * EXPANDS ITS BONE SUBSTITUTES PRODUCT LINE
    * ANNOUNCES RENEWAL AND EXTENSION OF EXCLUSIVE WORLDWIDE
LICENCE
WITH GRAFTYS AND ADDITION OF A HIGHLY INJECTABLE BONE SUBSTITUTE
TO ITS PORTFOLIO
    * RENEWAL AND EXTENSION OF PARTNERSHIP WITH GRAFTYS ALSO
CONCLUDES
ANY DIVERGENCE IN POSITION REGARDING EACH COMPANY'S IP THAT WERE
COMMUNICATED PREVIOUSLY, WITH NO CHANGE RELATED TO THERAVET'S IP

Source text for Eikon:  ID:nBw5zJ50Da 
Further company coverage:  ALVET.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))